Aidoc, which provides AI medical imaging software to flag incidental findings on CT scans and X-rays, raised a $150M Series E, taking its total funding to $520M
Aidoc, a clinical AI medical imaging provider, raised $150 million in Series E funding, CEO Elad Walach tells Axios Pro exclusively.
Context & Ripple Effects
Aidoc has repeatedly raised capital to expand AI tools that help radiologists interpret CT scans and X-rays: from its extended Series B through a $66M round and a $110M Series D. The coverage then broadened its positioning from scan analysis toward real-time clinical decision support built around its CARE foundation model.
This new Series E continues that financing arc at a larger cumulative scale, with health-system participation alongside specialist investors. It matters because funding is being directed not just at image-reading algorithms but at embedding clinical AI in care workflows.
First-order effects
- Aidoc gains $150M to continue developing and deploying its imaging and clinical-decision-support products, taking reported total funding to $520M.
- The company’s health-system backers have a direct incentive to help validate and operationalize its tools in clinical settings, while radiology and care teams gain a better-capitalized supplier for incidental-finding workflows.
Second-order effects
- Competing clinical-imaging AI vendors face a higher bar to match Aidoc’s funding, product breadth, and access to health-system deployment partners.
- Health systems evaluating AI imaging tools may place more weight on vendors that can support integration beyond a single detection use case, favoring platforms that connect imaging alerts to downstream clinical decisions.
Third-order effects
- If this pattern persists, clinical AI may consolidate around vendors able to finance the long path from model development to workflow integration and health-system adoption, rather than around stand-alone imaging algorithms.
- The shift from radiology assistance toward broader decision support will make evidence of clinical utility and interoperability increasingly central differentiators; the corpus does not establish which vendor model will prevail.
The trend: Clinical AI funding is moving toward platform-scale companies that pair imaging models with workflow-level decision support and health-system distribution.